<p>Example of 384-well plate data presented as a scatterplot. Each plate was screened with positive (purple) and negative (blue) controls consisting of streptavidin terbium and ABL-eGFP with and without RIN1-SBP, respectively. Screening compounds are represented in gray. The hit cutoff was a plate-based 3-standard deviation decrease in the FRET ratio.</p
<p>A, <i>left panel</i>. Representative image of realtime monitoring of Ca<sup>2+</sup>-mobilization...
<p><b>A.</b> Scheme of the plate design in 96-well format for compounds screening. <b>B. Left, </b><...
<p> (<b>A</b>) Variance accounted for by each of the principal components (PCs). (<b>B–D</b>) Scatte...
For each compound (dots), the relative GFP fluorescence of the screening target in the primary scree...
<p>Raw fluorescence data from the Spectrum screen were normalized to the assay controls on each plat...
<p>TOP: scattergram of percent inhibition data from all plates in the Genzyme HTS. Green: 100% inhib...
<p>(A) Plate layout for screening BSH inhibitors. Pink boxes (columns 3–22) indicate test wells that...
<p>A. Composite heat map of 99 384-well plates used for the pilot screen using the full complement o...
<p>(<b>A.</b>) Percent activity scatterplot for all bioactive compounds screened at single point (12...
<p>Scatter plot of screening data for a small library of known bioactive small molecules using the P...
<p>(A) Compounds screened ranked by percent inhibition and normalized to negative and positive contr...
<p>A) The S/N ratio (▪) and S/B ratio (•) were calculated from control wells on each of the 8 384 we...
<p><b>A.</b> Correlation of corresponding wells from duplicate plates in the library. Wells with few...
<p>S/B = signal to background. Hits are expressed as % inhibition. S/B and Z-factors were calculated...
<p>(A) Single point hit confirmation assay was an analysis of each of the initial hits in a 384-well...
<p>A, <i>left panel</i>. Representative image of realtime monitoring of Ca<sup>2+</sup>-mobilization...
<p><b>A.</b> Scheme of the plate design in 96-well format for compounds screening. <b>B. Left, </b><...
<p> (<b>A</b>) Variance accounted for by each of the principal components (PCs). (<b>B–D</b>) Scatte...
For each compound (dots), the relative GFP fluorescence of the screening target in the primary scree...
<p>Raw fluorescence data from the Spectrum screen were normalized to the assay controls on each plat...
<p>TOP: scattergram of percent inhibition data from all plates in the Genzyme HTS. Green: 100% inhib...
<p>(A) Plate layout for screening BSH inhibitors. Pink boxes (columns 3–22) indicate test wells that...
<p>A. Composite heat map of 99 384-well plates used for the pilot screen using the full complement o...
<p>(<b>A.</b>) Percent activity scatterplot for all bioactive compounds screened at single point (12...
<p>Scatter plot of screening data for a small library of known bioactive small molecules using the P...
<p>(A) Compounds screened ranked by percent inhibition and normalized to negative and positive contr...
<p>A) The S/N ratio (▪) and S/B ratio (•) were calculated from control wells on each of the 8 384 we...
<p><b>A.</b> Correlation of corresponding wells from duplicate plates in the library. Wells with few...
<p>S/B = signal to background. Hits are expressed as % inhibition. S/B and Z-factors were calculated...
<p>(A) Single point hit confirmation assay was an analysis of each of the initial hits in a 384-well...
<p>A, <i>left panel</i>. Representative image of realtime monitoring of Ca<sup>2+</sup>-mobilization...
<p><b>A.</b> Scheme of the plate design in 96-well format for compounds screening. <b>B. Left, </b><...
<p> (<b>A</b>) Variance accounted for by each of the principal components (PCs). (<b>B–D</b>) Scatte...